铂类抗肿瘤药的进展与临床评价

被引：65

作者：

林晓雯

张艳华

机构：

[1] 北京大学临床肿瘤学院北京肿瘤医院暨北京市肿瘤防治研究所恶性肿瘤发病机制及转化研究教育部重点实验室

来源：

中国医院用药评价与分析 | 2011年 / 11卷 / 01期

关键词：

铂类; 抗肿瘤药; 临床评价;

D O I：

10.14009/j.issn.1672-2124.2011.01.020

中图分类号：

R979.1 [抗肿瘤、抗癌药物];

学科分类号：

100403 [营养与食品卫生学];

摘要：

目的:探讨铂类抗肿瘤药的临床特点及其研究进展,为临床应用提供参考。方法:通过查阅国内外相关文献,系统地了解铂类抗肿瘤药的临床作用及相关不良反应;并检索近年上市、未获批准及正在进行临床研究的铂类药物,以分析其临床发展趋势。结果与结论:在过去的10年间,药物研发转向注重药物运输靶向介质,这些新药在保留传统铂类化合物的活性的同时,在很大程度上减少了传统铂类药物的不良反应。

引用

页码：4 / 7

页数：4

共 13 条

[1]

Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma [J].

Gong, Youling ;

Ren, Li ;

Zhou, Lin ;

Zhu, Jiang ;

Huang, Meijuan ;

Zhou, Xiaojuan ;

Wang, Jin ;

Lu, You ;

Hou, Mei ;

Wei, Yuquan .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (02) :327-333

[2]

Multicenter phase 2 study of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma [J].

Kurita, Hiroshi ;

Yamamoto, Etsuhide ;

Nozaki, Shinichi ;

Wada, Shigehito ;

Furuta, Isao ;

Miyata, Masaru ;

Kurashina, Kenji .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (03) :503-508

[3]

9088 Phase III study of Lipoplatin plus Gemcitabine versus Cisplatin plus Gemcitabine in advanced NSCLC; interim analysis.[J].C. Kosmas;J. Angel;A. Athanasiou;A. Rapti;C. Karanikas;S. Lambaki;N. Politis;N. Mylonakis.EJC Supplements.2009, 2

[4]

ProLindac? (AP5346): A review of the development of an HPMA DACH platinum Polymer Therapeutic.[J].David P Nowotnik;Esteban Cvitkovic.Advanced Drug Delivery Reviews.2009, 13

[5]

Lipoplatin ™ Monotherapy: A Phase II Trial of Second-Line Treatment of Metastatic Non-Small-Cell Lung Cancer [J].

Ravaioli, A. ;

Papi, M. ;

Pasquini, E. ;

Marangolo, M. ;

Rudnas, B. ;

Fantini, M. ;

Nicoletti, S. V. L. ;

Drudi, F. ;

Panzini, I. ;

Tamburini, E. ;

Gianni, L. ;

Pasini, G. .

JOURNAL OF CHEMOTHERAPY, 2009, 21 (01) :86-90

[6]

Phase 1 Trial of Lipoplatin and Gemcitabine as a Second-line Chemotherapy in Patients With Nonsmall Cell Lung Carcinoma [J].

Froudarakis, Marios E. ;

Pataka, Athanasia ;

Pappas, Periklis ;

Anevlavis, Stavros ;

Argiana, Evangelia ;

Nikolaidou, Martha ;

Kouliatis, George ;

Pozova, Sofia ;

Marselos, Marios ;

Bouros, Demosthenes .

CANCER, 2008, 113 (10) :2752-2760

[7]

Phase I and pharmacokinetic trial of AP5346; a DACH–platinum–polymer conjugate; administered weekly for three out of every 4 weeks to advanced solid tumor patients.[J].Mario Campone;Jeany M. Rademaker-Lakhai;Jaafar Bennouna;Stephen B. Howell;David P. Nowotnik;Jos H. Beijnen;Jan H. M. Schellens.Cancer Chemotherapy and Pharmacology.2007, 4

[8]

Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: A phase I-II study [J].

Stathopoulos, GP ;

Boulikas, T ;

Vougiouka, M ;

Rigatos, SK ;

Stathopoulos, JG .

ONCOLOGY REPORTS, 2006, 15 (05) :1201-1204

[9]

Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters [J].

Samimi, G ;

Howell, SB .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (06) :781-788

[10]

ZD0473 treatment in lung cancer: an overview of the clinical trial results.[J].J Treat;J Schiller;E Quoix;A Mauer;M Edelman;M Modiano;P Bonomi;R Ramlau;E Lemarie.European Journal of Cancer.2002,

← 1 2 →